We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Alzheimer's disease Diagnosed by Infrared Analysis of Leucocytes

By LabMedica International staff writers
Posted on 13 Feb 2012
Infrared analysis of white blood cells may possibly be a promising way to diagnose Alzheimer's disease (AD) more accurately.

The technique, which is noninvasive, fast, and low-cost, measures how much infrared radiation is either emitted or absorbed by white blood cells and measured by spectroscopy. More...


Scientists at the Instituto de Estructura de la Materia (Madrid, Spain) used two-dimensional infrared spectroscopy to measure and compare the infrared radiation emitted or absorbed by the leucocytes of healthy controls, versus those of patients with mild, moderate, and severe Alzheimer's disease. A total of 50 patients with Alzheimer's and 20 healthy controls took part in the study and gave blood samples. The white blood cells or mononuclear leukocytes are thought to carry amyloid-ß peptide in Alzheimer patients.

The infrared spectrum of the film of leucocytes was measured with a 1725X spectrophotometer (Perkin-Elmer; Waltham, MA, USA) with high resolution and obtained as an average of 32 scans. The scientists found significant differences in the range of infrared wavelengths displayed between subjects, which were attributable to the different stages of formation of amyloid-ß structures in the blood cells. The results showed that, with this method, healthy controls could be distinguished from mild and moderate sufferers of Alzheimer's disease. The method is being explored as a tool for early diagnosis.

The analysis showed a good test performance: 90% sensitivity and 90.5% specificity for determinations involving mild and moderate AD patients and age-matched healthy controls, and 82.1% sensitivity and 90.5% specificity for determinations involving patients at the three AD stages, mild, moderate, and severe, and age-matched healthy controls. The study demonstrated that AD is associated with higher percentages of β-structure in mononuclear leukocytes than those in healthy age-matched controls.

The authors concluded that the method they used could potentially offer a more simple detection of alternative biomarkers of Alzheimer's disease. Mononuclear leukocytes seem to offer a stable medium to determine ß-sheet structure levels as a function of disease development. The measurements seem to be more sensitive for earlier stages of Alzheimer's disease, namely mild and moderate. The study was published online on January 21 2012, in the journal Analytical and Bioanalytical Chemistry.

Related Links:
Instituto de Estructura de la Materia
Perkin-Elmer



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
All-in-One Molecular System
AIO M160
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image

FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing

Urinary tract infections are among the most common bacterial infections and a major driver of antibiotic prescribing, yet culture-based workflows can take days to produce results. Treatment often begins... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.